CELUW — Celularity Inc

Celularity Inc (CELUW) common stock listed on NASDAQ. It is led by Robert Joseph Hariri M.D., Ph.D., based in 170 Park Avenue, Florham Park, NJ, United States, 07932, with about 115 employees. Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Latest reported CELUW revenue for 2025-09-30 was $5.3M. Net income was -$23.1M. Revenue was down 7.9% from 2025-06-30 to 2025-09-30.

Use this CELUW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CELUW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CELUW SEC filings page. Lician reads the product cache first so this HTML stays unique to Celularity Inc even when a live quote feed is slow.